Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs [CNBC]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: CNBC
The pharmaceutical giant also raised its full-year revenue and adjusted earnings forecast. The results come as Bristol Myers moves to slash $1.5 billion in costs by 2025 and funnel that money into key drug brands and research and development programs. Bristol Myers Squibb on Thursday reported third-quarter earnings and revenue that blew past Wall Street's expectations thanks to its blockbuster blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term growth. The pharmaceutical giant also raised its full-year revenue guidance for the year, expecting sales to increase by more than 5%. Bristol Myers previously said it expected sales to rise in the "upper end" of the low single-digit range. The company also raised its 2024 adjusted earnings guidance to 75 cents to 95 cents per share, up from a previous forecast of 60 cents to 90 cents per share. The results come as Bristol Myers moves to cut $1.5 billion in costs by 2025 and funnel that money into key drug
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024 [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024Business Wire
- A promising schizophrenia drug showed mixed results. What does that mean for patients? [Yahoo! Finance Canada]Yahoo! Finance Canada
- A promising schizophrenia drug showed mixed results. What does that mean for patients? [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb Reports Third Quarter Financial Results for 2024Business Wire
BMY
Earnings
- 10/31/24 - Beat
BMY
Sec Filings
- 10/31/24 - Form 10-Q
- 10/31/24 - Form 8-K
- 10/3/24 - Form 4
- BMY's page on the SEC website